Literature DB >> 30662798

Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer.

Yuting Zhang1, Hongmei Zheng1, Yuting Zhan1, Mengping Long1, Sile Liu1, Junmi Lu1, Hongjing Zang1, Songqing Fan1.   

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in both men and women. The ability of cancer cells to break-off from the primary tumor and spread to distant organs is the main cause of death of cancer patients. The detection of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) is a considerable part of liquid biopsy, which contributes to the diagnosis, treatment and prognosis, and especially to identify the targetable mutations of NSCLC. This review is to discuss the detection and application of CTC and ctDNA in the diagnosis, prognostic evaluation and guiding targeted therapy of NSCLC.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); circulating tumor DNA (ctDNA); circulating tumor cells (CTCs); liquid biopsy; targeted therapy

Year:  2018        PMID: 30662798      PMCID: PMC6325475     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  3 in total

Review 1.  Circulating tumor cell profiling for precision oncology.

Authors:  Mahmoud Labib; Shana O Kelley
Journal:  Mol Oncol       Date:  2021-02-01       Impact factor: 6.603

Review 2.  The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance.

Authors:  Hassan Dianat-Moghadam; Mehdi Azizi; Zahra Eslami-S; Luis Enrique Cortés-Hernández; Maryam Heidarifard; Mohammad Nouri; Catherine Alix-Panabières
Journal:  Cancers (Basel)       Date:  2020-04-03       Impact factor: 6.639

3.  Identification of plasma exosomes long non-coding RNA HAGLR and circulating tumor cells as potential prognosis biomarkers in non-small cell lung cancer.

Authors:  Le Rao; Lihua Luo; Liufang Luo; Shan Chen; Ruizhi Ran; Xianling Liu
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.